Size | Price | Stock | Qty |
---|---|---|---|
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
25g |
|
||
50g |
|
||
Other Sizes |
|
Purity: ≥98%
Quetiapine Fumarate (Seroquel XR; IC-204,636; ICI204,636; ICI-204636), the fumarate salt of Quetiapine, is an atypical antipsychotic drug used for the treatment of schizophrenia, bipolar I mania, bipolar II depression, bipolar I depression. It unctions as an agonist of 5-HT receptors with a pEC50 of 4.77 for the human 5-HT1A receptor.
Targets |
Dopamine receptor; Histamine receptor; Adrenergic Receptor
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Animal Protocol |
|
||
References |
Molecular Formula |
C46H54N6O8S2
|
|
---|---|---|
Molecular Weight |
883.09
|
|
Exact Mass |
882.34
|
|
CAS # |
111974-72-2
|
|
Related CAS # |
Quetiapine; 111974-69-7; Quetiapine-d4 hemifumarate; 1217310-65-0; Quetiapine sulfoxide dihydrochloride; 329218-11-3; Quetiapine hemifumarate (Standard); 111974-72-2; Quetiapine-d4 fumarate; 1287376-15-1; Quetiapine-d8 fumarate; 1185247-12-4; Quetiapine-d8 hemifumarate; Quetiapine hemifumarate-d8; 1435938-24-1; Quetiapine sulfoxide; 329216-63-9
|
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
|
SMILES |
C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O
|
|
InChi Key |
ZTHJULTYCAQOIJ-WXXKFALUSA-N
|
|
InChi Code |
InChI=1S/2C21H25N3O2S.C4H4O4/c2*25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21;5-3(6)1-2-4(7)8/h2*1-8,25H,9-16H2;1-2H,(H,5,6)(H,7,8)/b;;2-1+
|
|
Chemical Name |
2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol;(E)-but-2-enedioic acid
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.66 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.66 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 0.5% CMC Na: 30mg/mL |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.1324 mL | 5.6619 mL | 11.3239 mL | |
5 mM | 0.2265 mL | 1.1324 mL | 2.2648 mL | |
10 mM | 0.1132 mL | 0.5662 mL | 1.1324 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04521478 | Active Recruiting |
Drug: BI 1358894 Drug: Placebo Drug: Quetiapine |
Depressive Disorder, Major | Boehringer Ingelheim | November 20, 2020 | Phase 2 |
NCT05801289 | Recruiting | Drug: Quetiapine | Delirium | Ain Shams University | December 4, 2022 | Not Applicable |
NCT05085808 | Not yet recruiting | Drug: Quetiapine Drug: Placebo |
Morality Delirium Psych |
University of Southern California | March 1, 2024 | Phase 4 |
NCT05240261 | Not yet recruiting | Drug: Quetiapine | Chronic Kidney Diseases | Assiut University | May 1, 2022 | Phase 1 |
NCT05480150 | Recruiting | Drug: Quetiapine Fumarate Tablets Drug: Lurasidone |
Major Depressive Disorder Bipolar Disorder, Mixed |
First Affiliated Hospital of Zhejiang University |
November 1, 2021 | Not Applicable |